Mesoblast Limited vs Plug Power Inc — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Plug Power Inc trades at $2.25 (market cap $2.98B). The key difference: Plug Power Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals.
| MESO | PLUG | |
|---|---|---|
Market Cap | $2.17B | $2.98B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $4.14 |
52-Week Low | $12.88 | $1.40 |
Enterprise Value | $2.17B | $3.77B |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Plug Power (PLUG) trades at $2.14, down 0.47% on the day, reflecting ongoing investor concerns about profitability despite recent contract wins. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -227.13% net income margin and negative cash flow. Recent news highlights a major 50MW Australian hydrogen project win, but operational challenges and dilution risks remain.
The outlook remains challenging with significant execution risks and cash burn, though analyst consensus suggests 36% upside to the $2.92 price target. Investment opportunity hinges on hydrogen adoption scaling faster than losses, while key risks include continued dilution, competitive pressure, and the company's ability to achieve profitability amid high debt levels.
Trailing returns across standard periods
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →